Status:

RECRUITING

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

National Institute on Aging (NIA)

Lundbeck LLC

Conditions:

Fronto-temporal Dementia

Fronto-temporal Lobar Dementia

Eligibility:

All Genders

45+ years

Phase:

PHASE2

Brief Summary

The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions thi...

Eligibility Criteria

Inclusion

  • FTD Patients
  • Male or Female
  • Age 45 and above
  • Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)
  • The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation
  • A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one
  • Patients must be medically stable
  • Vortioxetine treatment is clinically indicated
  • Competent to provide informed consent

Exclusion

  • No history of drug or alcohol dependence within six months prior to study entry
  • Negative toxicology screening for drugs of abuse
  • Subject must not be pregnant or nursing
  • No contraindications to Vortioxetine treatment
  • No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)
  • Healthy Controls
  • Inclusion Criteria:
  • Male or Female
  • Age 45 and above
  • Subjects must be medically stable
  • Free of psychotropic medications
  • Competent to provide informed consent

Key Trial Info

Start Date :

March 20 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2029

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06604520

Start Date

March 20 2025

End Date

September 1 2029

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Johns Hopkins Hospital

Baltimore, Maryland, United States, 21287